# T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

> **NCT00939653** · PHASE2 · TERMINATED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 6 (actual)

## Conditions studied

- Relapsed Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide
- **DRUG:** Filgrastim
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00939653
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-10
- **Primary completion:** 2011-07-15
- **Final completion:** 2011-07-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to insufficient research institution participation and patient enrollment
- **Last updated:** 2020-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939653, "T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00939653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*